Most data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case series. We aimed to compare, in a randomised trial, the efficacy and safety of prednisone alone with that of prednisone plus either methotrexate or ciclosporin in children with new-onset juvenile dermatomyositis.
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial / Ruperto, N., Pistorio, A., Oliveira, S., Zulian, F., Cuttica, R., Ravelli, A., Fischbach, M., Magnusson, B.o., Sterba, G., Avcin, T., Brochard, K., Corona, F., Dressler, F., Gerloni, V., Apaz, M.T., Bracaglia, C., Cespedes-Cruz, A., Cimaz, R., Couillault, G., Joos, R., et al.. - In: THE LANCET. - ISSN 0099-5355. - STAMPA. - 387:(2016), pp. 671-678. [10.1016/S0140-6736(15)01021-1]
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial
CIMAZ, ROLANDO;
2016
Abstract
Most data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case series. We aimed to compare, in a randomised trial, the efficacy and safety of prednisone alone with that of prednisone plus either methotrexate or ciclosporin in children with new-onset juvenile dermatomyositis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2016_Lancet_JDM.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
400.71 kB
Formato
Adobe PDF
|
400.71 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
